Aoxing Pharmaceutical Company, Inc. (AOXG)
OTCMKTS
· Delayed Price · Currency is USD
0.0085
0.00 (0.00%)
Jan 20, 2025, 4:00 PM EST
AOXG Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | 2011 - 2007 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '17 Mar 31, 2017 | Jun '16 Jun 30, 2016 | Jun '15 Jun 30, 2015 | Jun '14 Jun 30, 2014 | Jun '13 Jun 30, 2013 | Jun '12 Jun 30, 2012 | 2011 - 2007 |
| Revenue | 30.11 | 32.33 | 25.48 | 12.74 | 10.83 | 8.13 | Upgrade
|
| Revenue Growth (YoY) | -4.12% | 26.88% | 100.02% | 17.63% | 33.14% | 22.30% | Upgrade
|
| Cost of Revenue | 7.17 | 7.78 | 5.69 | 6.93 | 4.56 | 3.23 | Upgrade
|
| Gross Profit | 22.94 | 24.55 | 19.79 | 5.81 | 6.27 | 4.9 | Upgrade
|
| Selling, General & Admin | 18.99 | 14.68 | 10.21 | 7.96 | 10.75 | 4.88 | Upgrade
|
| Research & Development | 2.5 | 3.14 | 0.34 | 0.57 | 1.48 | 0.58 | Upgrade
|
| Operating Expenses | 21.97 | 18.33 | 11.1 | 9.15 | 12.82 | 6.05 | Upgrade
|
| Operating Income | 0.97 | 6.23 | 8.7 | -3.33 | -6.55 | -1.15 | Upgrade
|
| Interest Expense | -2.89 | -3.46 | -5.77 | -5.19 | -2.99 | -1.86 | Upgrade
|
| Earnings From Equity Investments | -0.03 | -0.09 | -0.09 | -0.1 | -0.11 | -0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.07 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.02 | 0.2 | 0.28 | - | 0.03 | 0.67 | Upgrade
|
| EBT Excluding Unusual Items | -1.87 | 2.89 | 3.11 | -8.63 | -9.62 | -2.48 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -7.06 | -13.4 | Upgrade
|
| Asset Writedown | - | - | - | - | -0.62 | - | Upgrade
|
| Pretax Income | -1.87 | 2.89 | 3.11 | -8.63 | -17.29 | -15.88 | Upgrade
|
| Income Tax Expense | -0.41 | 0.64 | -2.7 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -1.46 | 2.24 | 5.82 | -8.63 | -17.29 | -15.88 | Upgrade
|
| Minority Interest in Earnings | -0 | -0.18 | -0.32 | 0.42 | 0.49 | 0.06 | Upgrade
|
| Net Income | -1.46 | 2.06 | 5.49 | -8.22 | -16.8 | -15.82 | Upgrade
|
| Net Income to Common | -1.46 | 2.06 | 5.49 | -8.22 | -16.8 | -15.82 | Upgrade
|
| Net Income Growth | - | -62.49% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 76 | 74 | 63 | 50 | 50 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 75 | 63 | 50 | 50 | 49 | Upgrade
|
| Shares Change (YoY) | 5.60% | 19.47% | 26.70% | 0.21% | 0.82% | 5.94% | Upgrade
|
| EPS (Basic) | -0.02 | 0.03 | 0.09 | -0.16 | -0.34 | -0.32 | Upgrade
|
| EPS (Diluted) | -0.02 | 0.03 | 0.09 | -0.16 | -0.34 | -0.32 | Upgrade
|
| EPS Growth | - | -67.88% | - | - | - | - | Upgrade
|
| Free Cash Flow | -1.39 | -0.65 | 0.32 | -8 | -8.76 | -2.08 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.01 | 0.01 | -0.16 | -0.18 | -0.04 | Upgrade
|
| Gross Margin | 76.19% | 75.95% | 77.67% | 45.64% | 57.87% | 60.24% | Upgrade
|
| Operating Margin | 3.21% | 19.26% | 34.13% | -26.18% | -60.47% | -14.14% | Upgrade
|
| Profit Margin | -4.86% | 6.38% | 21.56% | -64.49% | -155.17% | -194.49% | Upgrade
|
| Free Cash Flow Margin | -4.63% | -2.02% | 1.26% | -62.79% | -80.86% | -25.55% | Upgrade
|
| EBITDA | 1.95 | 7.25 | 9.36 | -2.34 | -5.43 | -0.07 | Upgrade
|
| EBITDA Margin | 6.49% | 22.44% | 36.74% | -18.41% | -50.19% | -0.86% | Upgrade
|
| D&A For EBITDA | 0.99 | 1.03 | 0.67 | 0.99 | 1.11 | 1.08 | Upgrade
|
| EBIT | 0.97 | 6.23 | 8.7 | -3.33 | -6.55 | -1.15 | Upgrade
|
| EBIT Margin | 3.21% | 19.26% | 34.13% | -26.18% | -60.47% | -14.14% | Upgrade
|
| Effective Tax Rate | - | 22.26% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.